Mabion S.A. Logo

Mabion S.A.

Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.

MAB | WAR

Overview

Corporate Details

ISIN(s):
PLMBION00016 (+1 more)
LEI:
259400KG5JVQPPZL6X53
Country:
Poland
Address:
Konstantynów Łódzki GEN. MARIANA LANGIEWICZA 60, 95-050 Konstantynów Łódzki
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mabion S.A. is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services to pharmaceutical and biotech companies globally. The company specializes in the development, analytics, and manufacturing of complex biologic drugs. Mabion leverages advanced statistical methodologies, such as Design of Experiments (DoE), to optimize bioprocesses, enhance product quality, and ensure regulatory compliance. This data-driven approach supports accelerated development timelines and efficient, robust manufacturing for its partners, demonstrated through its involvement in large-scale production projects for biologics and vaccine components.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-24 21:15
Board/Management Information
Powołanie Prezesa Zarządu Spółki - Content (EN)
English 3.0 KB
2025-09-24 21:15
Board/Management Information
Powołanie Prezesa Zarządu Spółki - Content (PL)
Polish 2.8 KB
2025-09-19 17:14
Board/Management Information
Zmiana w składzie Zarządu Spółki - Content (EN)
English 805 bytes
2025-09-19 17:14
Board/Management Information
Zmiana w składzie Zarządu Spółki - Content (PL)
Polish 414 bytes
2025-09-12 15:05
Board/Management Information
Zmiana w składzie Zarządu Spółki - Content (EN)
English 812 bytes
2025-09-12 15:05
Board/Management Information
Zmiana w składzie Zarządu Spółki - Content (PL)
Polish 551 bytes
2025-09-05 17:55
Board/Management Information
Zmiany w składzie Zarządu Spółki - Content (PL)
Polish 5.8 KB
2025-08-18 16:17
Related Party Transaction
Rozszerzenie współpracy z Instituto De Biologia Molecular Do Paraná - IBMP popr…
Polish 2.2 KB
2025-07-29 17:59
Registration Form
Tekst Jednolitego Statutu Spółki
Polish 274.9 KB
2025-07-29 17:59
Registration Form
Przyjęcie tekstu jednolitego Statutu Spółki - Content (PL)
Polish 744 bytes
2025-07-23 17:36
Post-Annual General Meeting Information
Treść postanowień Statutu Mabion S.A. zmienionych uchwałą nr 3/VII/2025 Nadzwyc…
Polish 191.6 KB
2025-07-23 17:36
Registration Form
Rejestracja zmiany Statutu Spółki - Content (PL)
Polish 691 bytes
2025-07-14 13:32
Report Publication Announcement
Zmiana terminów publikacji raportów okresowych Spółki - Content (PL)
Polish 686 bytes
2025-07-11 14:48
Regulatory News Service
Zawiadomienie_korekta
Polish 82.0 KB
2025-07-11 14:48
Regulatory News Service
Zawiadomienie
Polish 81.4 KB

Automate Your Workflow. Get a real-time feed of all Mabion S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Mabion S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea 017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France NANO
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany NN6
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain NAT
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea 168330
Naturland Holding PLC Logo
A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.
United Kingdom NATUR
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220

Talk to a Data Expert

Have a question? We'll get back to you promptly.